May 24 (Reuters) - Theratechnologies
* Notified by partner of results for primary end point of
phase iii trial with ibalizumab in patients with multi-drug
resistant hiv-1
* Theratechnologies announces that 82.5% of patients
achieved the primary endpoint in the phase iii ibalizumab trial
Source text for Eikon: ID:nMKWhClwma
Further company coverage: TH.TO
(Bengaluru Newsroom: +1-646-223-8780)